Related Experiment Videos

The failure of immunomodulation therapy in heart failure: does the statins "paradigm" prove the rule?

Dimitris Tousoulis1, Nikolaos Papageorgiou, Alexandros Briasoulis

  • 11st Cardiology Unit, Hippokration Hospital, Athens University Medical School, Athens, Greece. drtousoulis@hotmail.com

Current Vascular Pharmacology
|June 3, 2009
PubMed

Insights

Statins, used for coronary artery disease, showed no clinical benefit in patients with chronic heart failure (CHF). Further large trials are needed to assess statins

Area of Science:

  • Cardiovascular Medicine
  • Immunology
  • Pharmacology

Background:

  • Inflammation plays a key role in atherosclerosis and coronary artery disease (CAD) complications.
  • Chronic heart failure (CHF) is linked to heightened inflammatory processes, with elevated pro-inflammatory cytokines (e.g., TNF-α, IL-6, IL-1) and adhesion molecules impacting prognosis.
  • Statins are effective in reducing morbidity and mortality in CAD patients, but their efficacy and safety in CHF populations require validation.

Purpose of the Study:

  • To evaluate the efficacy and safety of statin treatment in patients with chronic heart failure (CHF).
  • To investigate the anti-inflammatory properties of statins and their potential benefits in CHF.
  • To assess the impact of statins on immune imbalance in CHF patients.

Main Methods:

  • Review of several studies investigating statin use in CHF.
  • Analysis of recent randomized, double-blind, placebo-controlled trials on statins in CHF.
  • Examination of data on clinical outcomes and inflammatory markers in CHF patients undergoing statin therapy.

Main Results:

  • Statins did not demonstrate a significant effect on clinical outcomes in patients with CHF across various causes.
  • Previous findings suggesting benefits of statins in CHF, largely attributed to anti-inflammatory effects, are contradicted by recent trial data.
  • Current immunomodulation strategies, including statins, appear unsuccessful in managing heart failure.

Conclusions:

  • Statins do not improve clinical outcomes in patients with chronic heart failure (CHF).
  • The anti-inflammatory effects of statins do not translate into clinical benefit for CHF patients.
  • Larger clinical trials are necessary to explore the impact of statins on immune dysregulation and its potential restoration in CHF.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...